BeOne Medicines (ONC) Maintains 'Strong Buy' Rating Amid Robust Brukinsa Sales and FDA Catalysts

Key Facts

1Brukinsa sales grew 49% YoY to reach $3.93B in 2025.

2A 12-month price target of $410 per share was set with a 'strong buy' rating.

3Upcoming catalysts include potential FDA approvals for Sonrotoclax and BTK-CDAC.

BeOne Medicines (ONC) continues to demonstrate strong market momentum, supported by a 'Strong Buy' rating and a 12-month price target of $410 per share. The company's flagship drug, Brukinsa, reported a stellar 49% year-over-year growth in sales, reaching $3.93 billion in 2025. This performance solidifies the firm's leadership in the Chronic Lymphocytic Leukemia (CLL) market as it approaches a critical profitability inflection point. Looking ahead to 2026, investors are focused on several high-impact catalysts, including potential FDA approvals for Sonrotoclax and BTK-CDAC. Despite a modest miss in its 2026 guidance, the robust pipeline and core product growth suggest a positive long-term outlook for the biotech firm.